Pharmacy

Top Medical News
Jairia Dela Cruz, 2 hours ago
In the treatment of patients with community-acquired bacterial pneumonia (CABP), omadacycline is as effective as moxifloxacin at inducing response in patients with Pneumonia Patient Outcomes Research Team (PORT) risk class III and IV, according to data from the phase III OPTIC* trial.
3 hours ago
Cisplatin-ineligible patients with metastatic urothelial carcinoma treated with PD-1/L1 inhibitor followed by carboplatin-containing chemotherapy show similar overall survival (OS) with those treated with the reverse sequence, a study has found.
Audrey Abella, 6 hours ago
Amiselimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator, demonstrated a favourable safety profile among healthy individuals, according to a phase I study presented at Crohn’s and Colitis 2021.
10 hours ago
Use of vibegron in addition to α-1 blocker or phosphodiesterase 5 (PDE5) inhibitor is safe and effective in the treatment of patients with benign prostatic hyperplasia (BPH) and persistent storage symptoms, as shown in a study.
Roshini Claire Anthony, 22 hours ago

The combination of baricitinib and remdesivir improved recovery time and clinical status of patients with COVID-19 compared with remdesivir monotherapy, results of the ACTT*-2 study showed.

Elvira Manzano, 23 hours ago
The approval of the first COVID-19 vaccine came at a breakneck speed in December. Inoculation started in the US, liberating pent-up hopes that virus-ravaged states could get past the pandemic that has killed over 1.5 million people across continents.
Special Reports
Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas. 
Roshini Claire Anthony, 08 Jan 2021

Significant advancements in the treatment of acute lymphocytic leukaemia (ALL) in children have improved their outcomes. However, ALL treatment and eradication remain a major challenge in adults. In a recent webinar, two specialists from the US discussed current ALL treatment strategies and goals of future regimens.

Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Dr. Asok Kurup, Dr. Kenneth Chan, 07 Dec 2020
The rising incidence of infections caused by multidrug-resistant (MDR) gram-negative bacteria has become a serious health threat and a major challenge for intensivists. Against a backdrop of high patient mortality and risk factors for infection in intensive care units (ICU), early adequate therapy is of paramount importance. At a recent Pfizer-sponsored symposium, Dr Asok Kurup, Infectious Disease Physician, Singapore presented the implications of MDR gram-negative infections in critically ill patients in Asia, while Dr Kenneth Chan, Respiratory Physician and Intensivist, Singapore highlighted the role of ceftazidime-avibactam (Zavicefta) and shared published real-world data on ceftazidime-avibactam. 
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
01 Dec 2020
Dacomitinib 15 mg FC tab
Conference Reports
Pearl Toh, 26 Jan 2021
While children with inflammatory bowel disease (IBD) see their conditions improve with biologic therapy, those with ulcerative colitis (UC) tend to have residual disease activity even after clinical remission, according to two separate studies presented at the 2021 Crohn’s and Colitis Congress.
Audrey Abella, 26 Jan 2021
A meta-analysis presented at Crohn’s and Colitis 2021 demonstrated reductions in disease activity among adults with Crohn’s disease (CD) who were taking antibiotics.
Elaine Soliven, 26 Jan 2021
Patients with ulcerative colitis (UC) who received a subcutaneous (SC) formulation of vedolizumab as maintenance therapy achieved clinical remission at 52 weeks, according to the VISIBLE 1* trial presented at AIBD 2020.
Roshini Claire Anthony, 25 Jan 2021

The addition of chemotherapy to endocrine therapy improved invasive disease-free survival (IDFS) in premenopausal women with lymph node-positive early stage hormone receptor-positive (HR+) HER2-negative (HER2-) breast cancer with recurrence score 25, according to early results of the phase III SWOG S1007 RxPonder* trial presented at SABCS 2020. However, the benefits did not appear to extend to postmenopausal women.

Pearl Toh, 21 Jan 2021
The oral selective sphingosine-1-phosphate (S1P) receptor modulator ozanimod induced significant improvements in clinical remission and response, which were sustained up to 52 weeks, in patients with moderate-to-severe ulcerative colitis (UC), according to the phase III True North study presented at AIBD 2020 Congress.
Pearl Toh, 19 Jan 2021
Updates from the SECURE-IBD* registry reveal that treatment with thiopurine, either alone or in combination with tumour necrosis factor inhibitors (TNFis), for inflammatory bowel disease (IBD) was associated with a greater risk of severe COVID-19 compared with TNFis monotherapy.
Audrey Abella, 18 Jan 2021
An inverse association was found between the use of proton pump inhibitors (PPIs) and the severity of periodontal disease (PD), according to data presented at AIBD 2020.
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download